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Dementia is a clinical syndrome characterized by multiple cognitive deﬁcits and causes progressive neurodegeneration leading
eventually to death. The incidence of dementia is increasing worldwide with the increase in ageing population. However, no
eﬀective treatment is available yet. It has been hypothesized that drugs activating neurite outgrowth might induce neuronal
reconstruction and help in the recovery of brain function. Working on this hypothesis, we recently observed that the chloroform
extract of the Rosa damascena signiﬁcantly induced the neurite outgrowth activity and inhibited the Aβ(25–35)-induced atrophy
and cell death. Further workup led the isolation of a very long polyunsaturated fatty acid having molecular formula C37H64O2 as
an active constituent. The structure of this compound was established by extensive analysis of fragmentations observed in EI-MS
mode. The isolated compound protected Aβ(25–35)-induced atrophy and displayed strong neurite outgrowth activity. The length
of dendrite in the cells treated with this compound were comparable to those of nerve growth factor (NGF) treated cells.
1.Introduction
Dementia is one of the most burdensome health conditions
worldwide. Dementia causes progressive neurodegeneration
leading eventually to death. The incidence of dementia is
expected to increase with the increase in ageing popula-
tion. According to Alzheimer’s Disease International (ADI)
Delphi consensus study, an estimated 4.6 million people
suﬀer from dementia each year (one new case every 7s),
and81.1million peoplein theworldare likelytosuﬀerbythe
year 2040 [1]. Despite this catastrophic increase in dementia
patients worldwide, no eﬀective treatment is available yet.
Several acetylcholine esterase inhibitors such as donepezil,
rivastigmine and galantamine are most commonly used in
the treatment of dementia patients [2]. However, these only
slowdowntheprogressionofdementia,ratherthanrestoring
brainfunctioninareal clinicalsituation[3].Therefore,alter-
native therapeutic strategies are urgently needed. Dementia
is caused by neuronal degeneration and atrophy. Neurode-
generation in the central nervous system is an irreversible
process; however, formation of new synapses might be pos-
sible through the activation of remaining healthy neurons
[4]. Therefore, reconstructing the synaptic formation in the
brain could be a one of the powerful strategies in dementia
treatment [5]. Reconstruction of neuronal network and
synaptogenesis require neurite outgrowth as well as den-
dritic and axonal maturation steps. Therefore, drugs activat-
ing these steps could possibly initiate a recovery of brain
function.
Rosa damascena is commonly known as the Damask rose
and is renowned for its ﬁne fragrance. It is well known
for its relaxing eﬀects; traditionally, rose oil is used as a
remedy for anxiety, depression and for the treatment of stress
related conditions in many parts of the world [6]. Intraper-
itoneal injection of R. damascena essential oil retarded the
development of seizure stages in rats [7]. Taken together,
we suspected that rose oil might have eﬀects on the brain
function, but the eﬀect of R. damascena on atrophy of neu-
rites has never yet been investigated.2 Evidence-Based Complementary and Alternative Medicine
Amyloid β (Aβ) is thought to be a major pathological
cause of Alzheimer’s disease. Aβ(25–35) is a partial fragment
of a full peptide of Aβ and can be produced in brains of
Alzheimer’sdiseasepatientsbyenzymaticcleavageofthenat-
urally occurring Aβ(1–40) [8]. Aβ(25–35) similarly forms a
β-sheet structure[9],andinducesneuronalcelldeath[9,10],
neurite atrophy [11, 12], synaptic loss [11–13], and memory
impairment [11, 13–15]. Moreover, our previous work also
demonstrated that Aβ(25–35) and Aβ(1–42) resulted in
similar eﬀects on neuritic atrophy and cell death at 10μM
[16]. Furthermore, a recent report showed that a single
intracerebroventricular (i.c.v., 15μg) injection of Aβ(25–35)
could induce major neuropathological signs related to early
stages of Alzheimer’s disease in rats [17]. Considering those
reports, we have used Aβ(25–35) to induce neuritic atrophy
and cell death for preparing in vitro and in vivo models of
Alzheimer’s disease.
In this study, we have found that the chloroform extract
of the R. damascena (Rosaceae family, collected from the
Kashan market in Iran) showed strong neurite outgrowth
activity under Aβ(25–35)-induced neuritic atrophy condi-
tion and identiﬁed its active constituent in the extract.
2.Methods
2.1. General Methods. NMR spectra were taken on a JEOL
JNM-LA400 spectrometer with tetramethylsilane (TMS) as
an internal standard. HR-EI-MS measurements were per-
formed on a JEOL JMS-700T spectrometer using a direct
inlet system at the ionization voltage of 70eV. Medium
pressure liquid chromatograph (MPLC) was performed with
B¨ UCHI MPLC system using a normal BW-820MH silica
gel (Fuji Silysia, Aichi, Japan) (column size: 4.0 × 15cm).
Analytical and preparative TLC was carried out on precoated
silicagel60F254 orRP-18F254 plates(Merck,0.25or0.50mm-
thickness). Decosahexaenoic acid (DHA) and Mead acid
used in this study were purchased from Sigma Aldrich.
2.2. Extraction and Isolation. The buds of R. damascena
(500g) was purchased from the commercial supplier in
2005. The bud (400g) was extracted with chloroform under
sonication (1L × 1.5h × 3 times) to give chloroform extract
(18g). The chloroform extract (16g) was subjected to
MPLC (B¨ UCHI) on silica gel packed column (4.0 × 15cm)
eluted with hexane followed by methanol-chloroform sol-
vent system to give nine fractions. Fraction 4 (350mg) was
subjected to preparative TLC in 10% ethyl acetate-hexane
to aﬀord four subfractions (4–1, 60mg; 4–2, 75mg; 4–3,
80mg; 4–4, 55mg; 4–5, 40mg). Subfraction 4–3 was further
puriﬁed by repeated normal-phase preparative TLC with 2%
methanol-chloroform and acetone-benzene (1:9)to givethe
compound 1 (17.0mg).
2.2.1. Compound 1
Colorless Amorphous Solid. 1H NMR (400MHz, CDCl3) δ:
0.97 (3H, t, 7.4Hz, H-37), 1.22–1.37(36H, m, H-4–21),1.62
(2H, m, H-3), 2.05 (4H, m, H-22, 36), 2.34 (2H, t, 7.5 Hz,
H-2), 2.8 (6H, m, H-25, 28, 33), 5.32–5.38 (10H, m, H-24,
25, 27, 28, 30–33, 35, 36); EI-MS (rel int %) m/z: 540 (41),
523 (45), 507 (42), 492 (37), 479 (21), 470 (59), 458 (31),
457 (96), 438 (28), 421 (28), 419 (100), 402 (26), 382 (30),
362 (18), 345 (19), 327 (46), 305 (21), 287 (14), 271 (12),
268 (13), 249 (18), 241 (23), 217 (20), 215 (30), 212 (19),
142 (27), 137 (34), 128 (30), 125 (35), 97 (45), 68 (77), 54
(82), 40 (92), 21 (78). HR-EI-MS m/z: 540.4898 (M)+ calcd
for C37H64O2, 540.4906.
2.3. Primary Culture. All animal experiments were per-
formed in accordance with the Guidelines for the Care and
Use of Laboratory Animals of Sugitani Campus of the Uni-
versity of Toyama and NIH Guidelines on the Care and Use
of Laboratory Animals. All protocols were approved by the
Committee for Animal Care and Use of Sugitani Campus of
the University of Toyama. All eﬀorts were made to minimize
the number of animals used. Embryos were removed from
pregnant Sprague-Dawley rats (Japan SLC, Shizuoka, Japan)
at 18 days of gestation. The cortices were dissected and
the dura mater was removed. The tissues were minced and
dissociated and then grown in cultures with Neurobasal
medium (Gibco BRL, Rockville, MD, USA), including 12%
horse serum, 0.6% d-glucose and 2mM l-glutamine on
8-well chamber slides (Falcon, Franklin Lakes, NJ, USA)
coated with 50μg/mL poly-d-lysine at 37◦Ci nah u m i d i ﬁ e d
incubator with 10% CO2. When compounds were added,
half of the medium in each well was replaced with fresh
medium containing 2% B-27 supplement (Gibco BRL)
without serum. The time schedules of the experiments are
illustrated at the bottom of each respective ﬁgure. A partial
fragment of Aβ,A β(25–35) (Sigma-Aldrich, Saint Louis,
MO, USA), was dissolved in sterile distilled water (in vitro
experiments) or physiological saline (in vivo experiments)
at a concentration of 5mM and was incubated at 37◦Cf o r
4 days to allow ﬁbril formation. Recombinant rat NGF was
purchased from R&D Systems (Minneapolis, MN, USA) was
used as a positive control reagent.
2.4. Immunocytochemistry. Rat cortical neurons were cul-
tured in 8-well chamber slidesat a density of1.45 × 105 cells/
cm2. To measure the lengths of axons and dendrites, the
cells were treated with each extract, compound or vehicle
(0.1% DMSO). The cells were ﬁxed with 4% paraformalde-
hyde and then immunostained with a monoclonal anti-
body against phosphorylated neuroﬁlament-H (pNF-H)
(1:500)asanaxonal markerorapolyclonalantibody against
MAP2 (1:500) as a dendritic marker. Alexa Fluor 488-
conjugated goat anti-mouse IgG (1:300) and Alexa Fluor
568-conjugated goat anti-rabbit IgG were used as second
antibodies. A monoclonal antibody against pNF-H was
purchased from Sternberger Monoclonals (Lutherville, MD,
USA). A polyclonal antibody against microtubule-associated
protein 2a and 2b (MAP2) was purchased from Chemicon
(Temecula, CA,USA).Alexa Fluor488-conjugatedgoat anti-
mouse IgG and Alexa Fluor 568-conjugated goat anti-rabbit
IgG were purchased from Molecular Probes (Eugene, OR,
USA). Fluorescent images were captured by a ﬂuorescentEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Protective eﬀects of rose extract on Aβ(25–35)-induced dendritic atrophy and cell death. Cortical neurons were cultured for three
days and were then treated with (Veh) or without 10μMA β(25–35) (Cont). Cells were simultaneously treated by the chloroform extract of
Rosa damascena (0.5, 5μg/mL, RE) or vehicle (0.1% DMSO, Veh). (a) Five days after treatment, the cells were ﬁxed and immunostained for
MAP2a&2b.ThelengthsofMAP2a&2b-positiveneurites were measured.Valuesaremeans ±SEofdatafromfourareas.(b) After cultivation
for three days, the cortical neurons were treated with (Veh) or without (Cont) 10μMA β(25–35). The cells were simultaneouslytreated with
the chloroform extract of Rosa damascena (5μg / m L ,R E ) ,( G l y 14)-Humanin (100nM, HN) or vehicle (Veh). Four days after the treatment,
cell viability was measured. Values are means ± SE of data from sex areas. ∗P < 0.05 versus Aβ(25–35)/Veh (one-way ANOVA followed by
Dunnett’s post hoc test). Typical photographs were shown.
microscope (AX-80, Olympus, Tokyo, Japan) at 320 × 425
μm2, and four images were captured per treatment. The
lengths of neurites positive for pNF-H or MAP2 were mea-
sured using an image analyzer Neurocyte (Kurabo, Osaka,
Japan), which automatically traces and measures neurite
lengths without measuring cell bodies. The total length
of axons or dendrites was divided by cell numbers in an
identical area to calculate the average length per cell.4 Evidence-Based Complementary and Alternative Medicine
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Figure2:Protective eﬀects ofdiﬀerent fractionsofchloroformroseextract onAβ(25–35)-induced atrophiesofdendrites andaxons.Cortical
neuronswereculturedforthreedaysandwerethentreatedwith(Veh)orwithout10μMAβ(25–35)(Cont).Cellsweresimultaneouslytreated
by the chloroform extract of Rosa damascena (5μg/mL, RE), subfractions of the chloroform extract (5μg/mL), NGF (100ng/mL) or vehicle
(0.1% DMSO, Veh). Five days after treatment, the cells were ﬁxed and immunostainedfor MAP2a&2b (a) or phosphorylated NF-H (b). The
lengths of MAP2a&2b-positive neurites or phosphorylated NF-H-positive were measured. Values are means ± SE of data from four to six
areas. ∗P < 0.05 versus Aβ(25–35)/Veh (Student’s t-test). Typical photographs were shown.
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Figure 3: Structure of compound 1.
2.5. Cell Viability Assessment. Rat cortical neurons were
cultured in 8-well chamber slides at a density of 1.45 ×
105 cells/cm2. Cell viability was determined by calcein stain-
ing.Cellson8-wellchamberslideswererinsedbyphosphate-
buﬀer saline (PBS), and were incubated with 6μMc a l c e i n
AM (Dojindo, Kumamoto, Japan) for 40min at 37◦C. After
rinsing byPBS, cells were ﬁxed by 4% paraformaldehyde and
mounted. Fluorescence images were captured (six images
per treatment) by AX-80 microscope. The area of calcein-
positive cells per ﬁxed area (320 × 425μm2) was calculated
for estimating the percentage of living cells.
2.6. Statistical Analysis. Statistical comparisons were per-
formedwithone-wayanalysisofvariance(ANOVA)followed
by Dunnett’s post hoc test (Figure 1), or Student’s t-test
(Figures 2 and 5) using SigmaStat 3.5 (SYSTAT, CA, USA).
Values of P < 0.05 were considered signiﬁcant. The means of
the data are presented together with the standard error (SE).
3.Results
3.1. Eﬀect of Rose Extract and Its Fractions against Aβ(25–35)
Induced Atrophy. The chloroform extract of R. damascene
(RE) was added to the culture medium at a concentration of
0.5 and 5μg/mL orvehicle(Control, 0.1% DMSO).Five days
after the treatment, the length of dendrites were measured
(Figure 1(a)). The dendrite length was signiﬁcantly de-
creased by Aβ(25–35) induced neurite atrophy, while, treat-
ment with RE signiﬁcantly inhibited the Aβ(25–35)-inducedEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: EI-MS spectra and characteristic product ions observed for compound 1.
atrophy in a concentration dependent manner. In addition,
t h ec e l ls u r v i v a li nt h ev e h i c l eg r o u pw a sf o u n dt ob e
signiﬁcantly lower. While treatment of RE (5μg/mL) led the
signiﬁcant increase in thecellviability(Figure 1(b)).(Gly14)-
Humanin (100nM)wasusedasa positivecontrol[18]inthis
study also showed signiﬁcantly higher cell survival.
In order to ﬁnd out the active constituent that induced
neurite outgrowth activity in the chloroform extract of Rose
extract, it was subjected to column chromatography in silica
gel using gradient methanol-chloroform solvent system to
obtain nine fractions. Each of these fractions were again
tested for Aβ(25–35)-inducedatrophy. As shown in Figure 2,
the vehicle group showed the decrease in length of dendrites
and axons. Of these tested fractions, fraction-4 showed
pronounced eﬀect with signiﬁcant increase in the length
of dendrites and axons; therefore, fraction-4 was further
puriﬁedbyrepeated preparativeTLCinethylacetate-hexane,
2% methanol-chloroform and acetone-benzene (1:9) to
obtain compound 1 (Figure 3).
3.2. Identiﬁcation of Compound 1 and Its Neurite Outgrowth
Activity. Compound 1 was isolated as colorless amorphous
solid. It showed the HR-EI-MS at 540.4898 (calculated
for C37H64O2, 540.4906). The 1H NMR displayed signals
characteristic of unsaturated fatty acid and showed the sig-
nals ascribable to oleﬁnic protons δH 5.30–5.43ppm, allylic
protonsatδH 2.34ppm,methylenesatδH 1.20–1.37ppmand
methyl group at δH 0.97ppm. The 13CN M Rs p e c t r u mo n
the other hand displayed the signals corresponding to acid
carbonyl at δC 179.6ppm and 10 olifenic carbons carbons
(δC 132.0, 130.3, 130.2, 128.28, 128.26, 128.1, 127.9, 127.8,
and 127.1ppm). This partial information was coupled with
the EI-MS data, and subjected to extensive analysis of MS
fragmentation study. Natural product derived PUFAs had
methylene-interrupted double bonds of cis-geometry and
belonged to either n−3o rn−6f a m i l y[ 19]. The classiﬁation
n−3o rn−6 fatty acids are based on the ﬁrst double bond
that occurs either three or six carbon atoms from the methyl
terminus of the fatty acid molecule, respectively. With
this information in hand, EI-MS fragmentation analysis
(Figure 4) was done as follows.
The compound 1 displayed the molecular ion peak at
m/z 540. The peak at m/z 523, and 507 were indicative of
[M−OH]+ and [(M−OH)−16]+. A commercially available
mead acid was also studied for its fragmentation pattern,
which also gave similar fragment peaks corresponding to
[M]+,[ M −OH]+ and [(M−OH)−16]+, as in compound 1.6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Protective eﬀect of compound 1 on Aβ(25–35)-induced
dendritic atrophy.Cortical neuronswerecultured forthreedaysand
were then treated with (Veh) or without 10μMA β(25–35) (Cont).
Cells were simultaneously treated by compound 1 (1μM), sub-
fraction F-4 (5μg/mL), DHA (1μM), NGF (100ng/mL) or vehicle
(0.1% DMSO, Veh). Five days after treatment, the cells were ﬁxed
and immunostained for MAP2a&2b. The lengths of MAP2a&2b-
positive neurites were measured. Values are means ± SE of data
from four areas. ∗P < 0.05 versus Aβ(25–35)/Veh (Student’s t-test).
Typical photographs were shown.
The intense fragment at 478 is indicative of [507-Et]+ sug-
gesting compound 1 belongs to n−3 polyunsaturated fatty
acid. The sharp intense peak at m/z 419 corresponding to
[M−121]+ is due to allylic cleavage α fragment ion, while
another sharp peak at m/z 457 resulted from [M−83]+.I n
order to address these two major intense peaks, the ﬁve
double bonds should be located at Δ23, 26, 29, 31, and 34,
respectively. The peak corresponding to 215 and 325 were
indicative for cleavage of the [M]+ peak corresponding to α
and ω fragments at allylic C-21 position. Similarly peaks at
m/z 212,327,and268,271correspondstoαand ω fragments
of the [M−H]+ peaks, respectively. Thus, thorough analysis
of EI-MS fragmentation led the identiﬁcation of the com-
pound as C37:5 (Δ 23, 26, 29, 31, 34) fatty acid.
Compound 1 was tested for its Aβ(25–35)-induced atro-
phy. As shown in Figure 5, compound 1 showed activity at
ad o s eo f1μM. The eﬃcacy of compound 1 was compared
with nerve growth factor (NGF) and docosahexaenoic acid
(DHA). DHA is essential fatty acid praised for the memory
enhancement [20]. Interestingly, compound 1 displayed
stronger activity than DHA. Furthermore, the length of den-
drite in thecells treated with compound1 was comparableto
those of NGF treated cells. This indicated that compound 1
as the one of the active constituent present in RE responsible
for the enhancement of neurite outgrowth.
4.Discussion
Dementia is a clinical syndrome characterized by multiple
cognitive deﬁcits including signiﬁcant impairment in mem-
ory and at least one other sphere of mental activity [21]. The
two most common etiologies of dementia are Alzheimer’s
disease and vascular dementia. Estimates suggest that the
numbers of people with dementia worldwide in 2007 was
about 33-million, with a likely increase in the coming days
[1]. Despite this catastrophic increase in dementia patients
worldwide, no eﬀective treatment is yet available [22]. The
current treatment includes the use of cholinomimetic agents
in the form of acetylcholine esterase (AChE) inhibitors such
as donepezil, rivastigmine and galantamine; however, the
clinical eﬃcacy of these drugs is still controversial [3]. In this
regard, alternative medicines draw considerable attraction
these days as a source of potential new treatment for
dementia [5, 23, 24]. Natural medicines such as Withania
somnifera and ginseng saponins have been found to induce
axonal and dendritic extension [4, 25]; while in the present
study, we found that the chloroform extract of the R.
damascena signiﬁcantly induced the neurite outgrowth and
inhibited the Aβ(25–35)-induced atrophy. Furthermore, RE
prevents the neuronal cell death induced by Aβ(25–35). The
oil of R. damascena have been shown to relieve depression
and stress in humans [6], and has a relaxant eﬀect on guinea
pig tracheal chains [26]; however, this is the ﬁrst report on
the neurite outgrowth of rose extract. Further work up led
the isolation of very long chain polyunsaturated fatty acid
(VLFA) compound 1 belonging to n−3s e r i e sa so n eo ft h e
active constituents present in the extract. VLFAs are normal
components of most tissues, particularly brain, retina and
male reproductive tissues. VLFAs with 10–12 double bonds
and up to 58 carbon atoms have been reported from the
bovine retina [27]. Crustacea Bathynella baicalensis has been
shown to contain VLFAs with three to six double bonds
and up to 40 carbon atoms [28], while they have been
observed rarely in the plant kingdom. The present report is
the ﬁrst example about the occurrence of such VLFAs in R.
damascena.
Human development and health depend in many re-
spects on the availability of long chain polyunsaturated fatty
acids of 20 or 22 carbons in length that contain up to
six methylene-ﬂanked cis-double bonds [29]. Nutritionally
important VLFAs include the n−6 fatty acids such as arachi-
donic acid, and the n−3 fatty acids such as eicosapentaenoicEvidence-Based Complementary and Alternative Medicine 7
acid (EPA) and docosahexaenoic acid (DHA). In particular,
n−3 VLFAs have long been investigated for their importance
during human fetal development and the formation and
function of the central nervoussystem, brain and retina. The
lossofDHAinthebrainsofpatientswith Alzheimer’sdisease
is accompanied by a decrease in memory and learning [30].
DHAadministration protects against the oxidativestress and
loss of avoidance learning ability caused by the infusion of
Aβ into the cerebral ventricle [31]. Although it was reported
that DHA stimulated neurite outgrowth in normal neurons
such as rat primary hippocampal neurons [32]a n dP C 1 2
cells [33] ,n oo n eh a sr e p o r t e dt h ee ﬀect of DHA on Aβ-
induced neuritic atrophy. In present study, the compound 1
showed more pronounced protection of Aβ(25–35)-induced
neuritic atrophy than the DHA, suggesting the beneﬁcial
eﬀect against dementia.
Previous studiesindicated that saturated long-chain fatty
acids had no eﬀect on neurite extension [34, 35] and mam-
malian cells lack the desaturase enzymes that introduce
double bonds at the n−3a n dn−6 positions [36]. Therefore,
diets rich in these polyunsaturated fatty acid may have direct
beneﬁt for the human brain function. Although further
studies are required, the present study indicates the presence
of VLFAs in rose extract that might have possible health
beneﬁt for the patients suﬀering from dementia. Isolation
and identiﬁcation of other activec o n s t i t u e n t sa sw e l la ss y n -
thesis and semisynthesis of related compounds are essential
for the structure activity relationship study and thediscovery
of potent lead compound.
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